MedCity News November 9, 2021
The company started with genetic testing, but expanded to Covid-19 tests and vaccines during the pandemic. It’s valuation has tripled since it last raised a funding round valuing it at $1.5 billion in January.
Color recently raised $100 million in equity, tripling its valuation since it closed a funding round in January. It’s now valued at $4.6 billion.
Kindred Ventures and funds advised by T. Rowe Price Associates led its series E round.
Color, which had started as a genetic testing business in 2015, found a broader use for its infrastructure during the pandemic. The company grew quickly, operating thousands of Covid-19 testing sites, and is now looking at broader public health partnerships.
Before the pandemic, Color started working with...
Today's Sponsors
Today's Sponsor